Omnimap anti ms hrp

Manufactured by Roche

The OmniMap anti-Ms HRP is a laboratory equipment product. It is designed to perform a specific function within the laboratory setting. However, a detailed and unbiased description of the core function of this product cannot be provided while maintaining the requested level of conciseness and lack of interpretation or extrapolation. Therefore, the description for this product is not available.

Automatically generated - may contain errors

Lab products found in correlation

Ez prep solution, by Roche (1 mentions) Chromomap dab kit, by Roche (1 mentions) Ventana discovery ultra platform, by Roche (1 mentions) Cd20 clone l26, by Roche (1 mentions) Vectra polaris system, by PerkinElmer (1 mentions) Cd8 c8 144b, by Agilent Technologies (1 mentions) Cd3 2gv6, by Roche (1 mentions) Cd20 l26, by Roche (1 mentions) Optiview dab detection kit, by Roche (1 mentions) Ventana benchmark ultra system, by Roche (1 mentions)

2 protocols using omnimap anti ms hrp

Immunohistochemical Detection of PrP^sc

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissues were fixed in 10% formalin for processing for microscopic examination. Neuropathological methods and immunohistochemical detection of pathological prion protein (PrP^sc) were performed on brain sections as previously described56 (link). Briefly, PrP was detected using the Discovery Automated IHC Stainer. After dewaxing with Ventana EZ Prep solution, slides were sequentially incubated with the cell conditioner 1 protocol (CC1) for 48 minutes, guanidinium thiocyanate 4.0 M for 16 minutes, the primary mouse monoclonal antibody (3F4 or 12F10) for 40 minutes, the secondary anti-mouse antibody OmniMap anti-Ms HRP (Ventana) for 16 minutes. Reactions were developed with the ChromoMap DAB kit (Ventana).

Comoy E.E., Mikol J., Luccantoni-Freire S., Correia E., Lescoutra-Etchegaray N., Durand V., Dehen C., Andreoletti O., Casalone C., Richt J.A., Greenlee J.J., Baron T., Benestad S.L., Brown P, & Deslys J.P. (2015). Transmission of scrapie prions to primate after an extended silent incubation period. Scientific Reports, 5, 11573.

+ Open protocol

+ Expand

Multi-marker Immunohistochemistry Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

All stainings were carried out on 3 micrometers paraffin slides using a Ventana Discovery Ultra platform (Ventana, Roche Diagnostics). Double immunohistochemistry was performed on all cases with i) CD3 (2GV6, Ventana) combined to CD20 (L26, Ventana) and ii) CD8 (C8/144B, Dako) combined to PD-L1 (QR1, Diagomics). Stainings were performed with the protocol RUO discovery universal according to the manufacturer’s recommendations with the detection kits OmniMap anti-Rb HRP (760-4311, Ventana) and OmniMap anti-Ms HRP (760-4310, Ventana). The slides were scanned using the PerkinElmer Vectra Polaris System. The double CD20-CD23 immunohistochemistry staining was performed with the primary antibodies CD20 (clone L26, Ventana) and CD23 (clone 1B12, Novocastra). The procedure was performed with a Ventana Benchmark Ultra system (Ventana, Roche Diagnostics) using the Ultraview AP RED and Optiview DAB detection kits (Ventana) following the manufacturer’s recommendations (double stain oDAB-uRED v5 protocol, Ventana).

Vanhersecke L., Brunet M., Guégan J.P., Rey C., Bougouin A., Cousin S., Moulec S.L., Besse B., Loriot Y., Larroquette M., Soubeyran I., Toulmonde M., Roubaud G., Pernot S., Cabart M., Chomy F., Lefevre C., Bourcier K., Kind M., Giglioli I., Sautès-Fridman C., Velasco V., Courgeon F., Oflazoglu E., Savina A., Marabelle A., Soria J.C., Bellera C., Sofeu C., Bessede A., Fridman W.H., Loarer F.L, & Italiano A. (2021). Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature cancer, 2(8), 794-802.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!